Biologic Market Research
Biologics include a wide range of medicinal products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins created by biological processes. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues.
Research indicates that the global biologics market is valued at an estimated $149 billion in 2010 and is expected to reach $239 billion by 2015, a compound annual growth rate (CAGR) of 9.9% from 2010-2015. It is further believed that the driving force behind this growth is the growing need for a more extensive drug pipeline, attractive targets against challenging diseases, a push to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.
Further studies highlight that Monoclonal antibodies (mAbs) comprised 31.9% of the 2009 market, or $43 billion. The mAb segment is projected to increase at the fastest rate within the total biologics market to $86 billion by 2015, from a value of $48 billion in 2010, a compound annual growth rate (CAGR) of 12.4%.
The Biologic market research reports incorporate trend analysis, statistics, market size information, industry growth rates, as well as market share of competitors. The comprehensive research also goes on to examine details such as technology & systems and domestic & international markets.
The study is an essential resource for top-level data and analysis covering the biologic industry. It includes detailed data on market size and segmentation, comprehensive analysis of the key trends and competitive landscape, and profiles of the leading companies.